Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors

Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of 
Directors 
Dynavax Meeting With FDA Scheduled First Half of June 
BERKELEY, CA -- (Marketwired) -- 04/30/13 --  Dynavax Technologies
Corporation (NASDAQ: DVAX) today announced that the Company's board
of directors has appointed Eddie Gray chief executive officer and a
member of Dynavax's board, effective May 1, 2013. Mr. Gray will
succeed Dino Dina, M.D., Chief Executive Officer. Dr. Dina will
remain a consultant to the Company for a transition period and plans
to continue serving as a member of the Dynavax board. The Company
also indicated that Tyler Martin, M.D., President, is departing from
Dynavax on May 31, 2013 and plans to remain a consultant for a
transition period.  
"With 30 years of pharmaceutical industry experience, Eddie has a
track record of success in building international commercial
organizations," said Dr. Dina, CEO. "His extensive executive and
operations-based background position him to lead the Company going
forward, and he will be a major contributor to driving sustainable
long-term value for Dynavax."  
"It is a privilege to be joining Dynavax at this exciting time in the
Company's history," said Mr. Gray. "I believe HEPLISAV(TM) represents
a significant commercial opportunity and I look forward to bringing
its unique benefits to patients." 
"On behalf of the Company, the members of the Dynavax board welcome
Eddie. We would also like to thank Dino for his dedicated leadership
over the last 15 years and to recognize Tyler for his significant
contributions to Dynavax in bringing the organization through a
critical period of development," said Arnold Oronsky, Chairman of the
Board.  
Most recently, Mr. Gray served as the President of Pharmaceuticals
Europe at GlaxoSmithKline plc (GSK) since 2008 and as Senior Vice
President and General Manager of Pharmaceuticals UK from 2001 through
2007. In both roles, he was instrumental in the launch,
commercialization and strategic development of GSK's vaccine
portfolio. Prior to the formation of GSK, Mr. Gray was with
SmithKline Beecham from 1988 through 2000 serving in various
positions of increasing responsibility, including Vice President and
Director of Anti-Infectives Marketing in the US, Vice President and 
Director of the Vaccines Business Unit in the US, and Vice President
and General Manager of Pharmaceuticals in Canada. Mr. Gray received a
Bachelor of Science degree in Chemistry and Management Studies from
the University of London and an MBA from the Cranfield School of
Management in the UK.  
HEPLISAV Update 
Dynavax also reported today that it will meet in the first half of
June with the US Food and Drug Administration (FDA) regarding the
Company's Biologic License Application (BLA) for HEPLISAV, an
investigational adult hepatitis B vaccine. The Company has been
working closely with the FDA to prepare for the meeting, the purpose
of which is to discuss the most expeditious path to approval for
HEPLISAV, following the Complete Response Letter issued in February
2013. Dynavax will provide updates as appropriate. 
About HEPLISAV  
HEPLISAV is an investigational adult hepatitis B vaccine for which US
and European licensure applications have been accepted for review by
the FDA and the EMA. Dynavax has worldwide commercial rights to
HEPLISAV. HEPLISAV combines hepatitis B surface antigen with a
proprietary Toll-like Receptor 9 agonist to enhance the immune
response.  
About Dynavax  
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical
company, discovers and develops novel products to prevent and treat
infectious and inflammatory diseases. The Company's lead product
candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B
vaccine. For more information visit www.dynavax.com.  
Forward-Looking Statements  
This press release contains "forward-looking" statements, including
expectations for HEPLISAV, Mr. Gray's potential contributions and our
meeting and plans for discussions with the FDA. Actual results may
differ materially from those set forth in this press release due to
the risks and uncertainties inherent in our business, including
whether successful clinical and regulatory development and review and
approval of HEPLISAV and our process for its manufacture can occur
without significant delay or additional studies; whether our studies
and manufacturing efforts can support registration for
commercialization of HEPLISAV; the results of clinical trials and the
impact of those results on the initiation and completion of
subsequent trials and issues arising in the regulatory process,
including whether a BLA or European licensure application will be
approved; our ability to obtain additional financing to support the
development and commercialization of HEPLISAV and our other
operations; possible claims against us, including enjoining sales of
HEPLISAV, based on the patent rights of others; and other risks
detailed in the "Risk Factors" section of our current periodic
reports with the SEC. We undertake no obligation to revise or update
information herein to reflect events or circumstances in the future,
even if new information becomes available. Information on Dynavax's
website at www.dynavax.com is not incorporated by reference in our
current periodic reports with the SEC.  
Contact:
Michael Ostrach
Vice President and Chief Business Officer 
510-665-7257
mostrach@dynavax.com